Key Highlights

● Third-quarter Revenue rose 36% to $5.12 billion from $3.75 billion a year earlier.

● Adjusted Earnings surged 70% to $20.07 a share against a $13.76 consensus.

● Dupixent global net sales reached $6.5 billion, up 35% from a year earlier.

● Regeneron raised its 2026 gross Margin forecast and bought back $2.3 billion of stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) shares were up 6.87% at $875.00 in pre-market trading as of 8:23 a.m. ET Friday, according to market data, after the biotech released third-quarter results before the open. One market headline said the stock hit two-year highs in pre-market trading after the quarter beat expectations.

A Blowout quarter before the bell

Total revenue rose 36% to $5.12 billion from $3.75 billion a year earlier, according to the company's release filed with the SEC. Adjusted earnings surged 70% to $20.07 a share, and GAAP earnings were $18.45 a share. A pre-week earnings calendar had listed a consensus of $13.76 a share, although that compilation does not say whether it is on an adjusted basis, so the size of the beat should be read with that caveat.

"This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales," chief executive Leonard Schleifer said. Finance chief Christopher Fenimore said the results position the company "to deliver one of our strongest years ever."

What drove the numbers

Dupixent, the eczema and asthma drug Regeneron co-develops with Sanofi (NASDAQ:SNY), posted global net sales of $6.5 billion, up 35%. Sanofi books those sales and Regeneron receives a share of the profits. An automated summary from market data also cites a shift to booking Regeneron's full Dupixent profit share, which may help explain the jump in revenue, though this was not confirmed against the release.

In ophthalmology, EYLEA HD US net sales rose 62% to $699 million while the older EYLEA fell 41% to $400 million, as patients switch to the higher-dose version. Cancer drug Libtayo grew 51% to $550 million globally. In August, the FDA also approved Pasatru, or garetosmab, for the rare bone disorder fibrodysplasia ossificans progressiva, adding a new product to the portfolio.

Regeneron also raised its 2026 non-GAAP gross margin forecast on product sales to about 86% from 84% to 85%, lifted its Research and Development budget to $6.05 billion to $6.15 billion and lowered its expected sales and administrative costs. An expanded antibody collaboration with Sanofi brought a $1.0 billion upfront payment with up to $7.0 billion more in potential milestones. The company bought back $2.3 billion of stock in the first nine months and declared a quarterly Dividend of 94 cents a share, payable December 3.

Index role, backdrop, risks and what to watch

Regeneron is a member of the Nasdaq-100 and the S&P 500, and its gain contrasts with a deep slide in technology: Nasdaq-100 futures were down about 2.6% around 8 a.m. ET, according to market quotes. Health care has drawn steady inflows as investors rotate out of AI-linked stocks; the sector fund hit a record on Thursday after a 2.4% gain, according to market data. Partner Sanofi was up 3.92% in US trading after raising its own guidance, market data showed.

Risks include the continued erosion of original EYLEA sales, competition in immunology as Dupixent matures, and drug-pricing policy, which could shift after Tuesday's midterm elections. Higher R&D spending also raises the bar for the pipeline to deliver.

Several catalysts are scheduled. Phase 2 results for baloncibart in POTS are due in November 2026. The FDA has accepted a resubmitted application for odronextamab, branded Ordspono, in a form of lymphoma with a target date in February 2027, and a decision on Libtayo as an adjuvant skin-cancer treatment is targeted for March 2027. In the near term, traders will watch whether the stock holds its two-year-high territory after the 9:30 a.m. ET open.